The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Kodiak Sciences Inc. is $61.50, about 41.7% above its August 12 closing price of $43.41.
Cash position and outlook
Company ended Q2 with $125.9 mln in cash and expects funding to last into 2027.
Kodiak says current cash and equivalents are expected to support operations into 2027.
Late-stage program updates
Company advanced Phase 3 trials for Zenkuda, KSI-501 and KSI-101; topline data expected in coming quarters.
Kodiak expects DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in September 2026.
Company anticipates PEAK Phase 3 Pivotal Analysis 1 topline data for KSI-101 in December 2026.
Q2 results and cost drivers
Retina-focused biotech's Q2 net loss widened year over year as R&D expenses increased.
Company said increased Q2 R&D expenses were mainly due to greater clinical and manufacturing activities for Phase 3 programs.
KOD•
